Fredun Pharmaceuticals Limited, a leading healthcare and pharmaceuticals company, has announced a momentous achievement in Freossi, its Pet care division, that has been receiving an extremely positive response and went completely stock out among the distributor channels. With this, the Company's annual run rate in the segment for FY24 stands at Rs. 20 crores.

With unyielding dedication and strategic planning, the company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision.

The remarkable achievement not only bolsters Fredun Pharma's competitive edge in this segment but also demonstrates its unwavering resolve to cater to the escalating demands of the market. The company has received an overwhelming response and positive feedback from its trade channels, reinforcing its belief in the potential of Freossi's offerings. This has created a stock-out situation at trade channels, which is a testimony for company's innovative products. As a result, Fredun Pharmaceuticals anticipates an exceptional growth trajectory, projecting to double the Pet division's turnover next year.

Commenting on the milestone achievement, Fredun Medhora, Managing Director of Fredun Pharmaceuticals said, "We are ecstatic with the initial response we have received for our pet care brand Freossi. It is establishing a strong presence pan India and becoming a preferred brand for most veterinarians. The pet sector in India is completely dominated by the MNCs. Fredun Pharma, with its highquality products and backward integration advantage, aims to be a significant pet player over the next five years."

Fredun Pharmaceuticals Limited remains committed to advancing its pet care division, striving to set new industry standards, and become a leading force in the pet care segment. With an unwavering focus on customer satisfaction, innovative products, and strong market presence, the company is well-poised for continued success and growth.